Literature DB >> 28864650

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Joanna C Robson1,2, Gunnar Tomasson1,2, Nataliya Milman1,2, Sue Ashdown1,2, Annelies Boonen1,2, George C Casey1,2, Peter F Cronholm1,2, David Cuthbertson1,2, Jill Dawson1,2, Haner Direskeneli1,2, Ebony Easley1,2, Tanaz A Kermani1,2, John T Farrar1,2, Don Gebhart1,2, Georgia Lanier1,2, Raashid A Luqmani1,2, Alfred Mahr1,2, Carol A McAlear1,2, Jacqueline Peck1,2, Beverley Shea1,2, Judy A Shea1,2, Antoine G Sreih1,2, Peter S Tugwell1,2, Peter A Merkel3,4.   

Abstract

OBJECTIVE: The antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are multiorgan diseases. Patients with AAV report impairment in their health-related quality of life (HRQOL) and have different priorities regarding disease assessment compared with physicians. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group previously received endorsement for a core set of domains in AAV. Two approaches to measure patient-reported outcomes (PRO) were presented at OMERACT 2016.
METHODS: A novel 5-step tool was used to facilitate assessment of the instruments by delegates: the OMERACT Filter 2.0 Instrument Selection Algorithm, with a red-amber-green checklist of questions, including (1) good match with domain (face and content validity), (2) feasibility, (3) do numeric scores make sense (construct validity)?, (4) overall ratings of discrimination, and (5) can individual thresholds of meaning be defined? Delegates gave an overall endorsement. Three generic Patient-Reported Outcomes Measurement Information System (PROMIS) instruments (fatigue, physical functioning, and pain interference) and a disease-specific PRO, the AAV-PRO (6 domains related to symptoms and HRQOL), were presented.
RESULTS: OMERACT delegates endorsed the use of the PROMIS instruments for fatigue, physical functioning, and pain interference (87.6% overall endorsement) and the disease-specific AAV-PRO instrument (89.4% overall endorsement).
CONCLUSION: The OMERACT Vasculitis Working Group gained endorsement by OMERACT for use of the PROMIS and the AAV-PRO in clinical trials of vasculitis. These instruments are complementary to each other. The PROMIS and the AAV-PRO need further work to assess their utility in longitudinal settings, including their ability to discriminate between treatments of varying efficacy in the setting of a randomized controlled trial.

Entities:  

Keywords:  ANCA-ASSOCIATED VASCULITIS; ICF; OMERACT; PATIENT-REPORTED OUTCOMES; PROMIS

Mesh:

Substances:

Year:  2017        PMID: 28864650      PMCID: PMC5951181          DOI: 10.3899/jrheum.161139

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  22 in total

1.  Development of ICF Core Sets for patients with chronic conditions.

Authors:  Alarcos Cieza; Thomas Ewert; T Berdirhan Ustün; Somnath Chatterji; Nenad Kostanjsek; Gerold Stucki
Journal:  J Rehabil Med       Date:  2004-07       Impact factor: 2.912

2.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

Review 3.  Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP.

Authors:  Peter P Cheung; Maarten de Wit; Clifton O Bingham; John R Kirwan; Amye Leong; Lyn M March; Pam Montie; Marieke Scholte-Voshaar; Laure Gossec
Journal:  J Rheumatol       Date:  2015-04-15       Impact factor: 4.666

4.  The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Haner Direskeneli; Karen Herlyn; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Raashid A Luqmani
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

5.  Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health.

Authors:  Nataliya Milman; Annelies Boonen; Peter A Merkel; Peter Tugwell
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-02       Impact factor: 4.794

6.  Wegener's granulomatosis: clinical course in 108 patients with renal involvement.

Authors:  K Aasarød; B M Iversen; J Hammerstrøm; L Bostad; L Vatten; S Jørstad
Journal:  Nephrol Dial Transplant       Date:  2000-05       Impact factor: 5.992

7.  Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative.

Authors:  L Gossec; M Dougados; N Rincheval; A Balanescu; D T Boumpas; S Canadelo; L Carmona; J-P Daurès; M de Wit; B A C Dijkmans; M Englbrecht; Z Gunendi; T Heiberg; J R Kirwan; E M Mola; M Matucci-Cerinic; K Otsa; G Schett; T Sokka; G A Wells; G J Aanerud; A Celano; A Dudkin; C Hernandez; K Koutsogianni; F N Akca; A-M Petre; P Richards; M Scholte-Voshaar; G Von Krause; T K Kvien
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

Review 8.  Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Authors:  Joanna C Robson; Nataliya Milman; Gunnar Tomasson; Jill Dawson; Peter F Cronholm; Katherine Kellom; Judy Shea; Susan Ashdown; Maarten Boers; Annelies Boonen; George C Casey; John T Farrar; Don Gebhart; Jeffrey Krischer; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Antoine G Sreih; Peter S Tugwell; Raashid A Luqmani; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-09-01       Impact factor: 4.666

9.  The characterisation and determinants of quality of life in ANCA associated vasculitis.

Authors:  Neil Basu; Andrew McClean; Lorraine Harper; Esther Nicole Amft; Neeraj Dhaun; Raashid A Luqmani; Mark A Little; David Rw Jayne; Oliver Flossmann; John McLaren; Vinod Kumar; Lars P Erwig; David M Reid; Gareth T Jones; Gary J Macfarlane
Journal:  Ann Rheum Dis       Date:  2013-01-25       Impact factor: 19.103

10.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Authors:  Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2013-11-15       Impact factor: 19.103

View more
  3 in total

Review 1.  Assessing Patient-Reported Outcomes in Pediatric Rheumatic Diseases: Considerations and Future Directions.

Authors:  Christina K Zigler; Rachel L Randell; Bryce B Reeve
Journal:  Rheum Dis Clin North Am       Date:  2022-02       Impact factor: 2.032

2.  Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health.

Authors:  Nataliya Milman; Eilish McConville; Joanna C Robson; Annelies Boonen; Peter Tugwell; George A Wells; Dipayan Chaudhuri; Jill Dawson; Gunnar Tomasson; Susan Ashdown; Don Gebhart; Georgia Lanier; Jacqueline Peck; Carol A McAlear; Katherine S Kellom; Peter F Cronholm; Peter A Merkel
Journal:  J Rheumatol       Date:  2019-02-01       Impact factor: 4.666

Review 3.  Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.

Authors:  Joanna C Robson; David Jayne; Peter A Merkel; Jill Dawson
Journal:  Patient Relat Outcome Meas       Date:  2019-02-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.